ÎÚÑ»´«Ã½

Along with SARS-CoV-2 and influenza, this virus has contributed to a brutal season for respiratory illness.

XBB.1.5 is the most transmissible variant of COVID-19 yet. As 2023 begins, it’s causing the majority of cases in the U.S., but we aren’t seeing a surge like omicron caused last winter.

Looking back at the biggest public health headlines of the year, from gun violence and reproductive rights to humanitarian and environmental crises. Plus: What to expect in 2023.

As year three of the COVID-19 era draws to a close, pandemic experts weigh in on the good, the bad, and the unknown of COVID-19 in 2022—and look ahead to 2023.

Research teams considered booster rates and potential new variants in their latest COVID-19 projections—which cover months when RSV and the flu could also send many people to the hospital.

More than 40 million people have died from HIV since the first cases of AIDS were reported in 1981. There is a need, and the funding exists, so where are the vaccines?

WHO’s latest tuberculosis report painted a bleak picture—showing  that TB incidence and mortality rose for the first time in almost 2 decades.

Can omicron’s multiple subvariants outpace COVID tests, vaccines, and treatments?

The hygiene hypothesis says exposure to germs helps kids develop healthy immune systems. But many viruses didn’t circulate as widely during the pandemic. Are there downsides to missed infections?

The inaugural director of the Lyme and Tickborne Diseases Institute tackles the growing threat of tickborne illnesses.

Battered by the pandemic’s challenges and pushed to their limits, researchers responded with resilience, creativity, and long hours.

Some SRH-related concerns provoke negative moral judgments that can influence everything from patient care to research funding.

The strength of people’s trust in their health leaders can determine how a country will fare in a pandemic. From the COVID-19 pandemic to the Ebola epidemic to the reemergence of monkeypox as a public health emergency, such trust has been low.

Findings suggest this group should be considered for additional vaccine dosages and other risk-reduction measures.

Combining proteins from two SARS-CoV-2 variants, bivalent booster shots protect against the currently circulating BA.5 subvariant—and may afford longer-lasting immunity.